Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

418461

	registered interest
	date	11/09/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Ehlers-Danlos Syndrome
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what recent assessment he has made of patient outcomes of those diagnosed with Ehlers-Danlos syndrome in (a) London and (b) Greater Manchester.
	tabling member constituency	Bury North
	tabling member printed	Mr David Nuttall
	uin	9987
	answer	answer is ministerial correction date of answer 21/09/2015 answer text <p>Information on patient outcomes of those diagnosed with Ehlers-Danlos Syndrome (EDS) in London and Greater Manchester is not held centrally by the Department. EDS falls within specialised services managed by NHS England.</p><p> </p><p> </p><p> </p><p>The UK Strategy for Rare Diseases sets out the Government’s on-going commitment to ensuring that patients with rare diseases, including EDS, have access to high quality services. The Strategy is discussed regularly with health bodies including NHS England. The national specialised service for atypical or complex cases aims to reduce times to diagnosis and reduce the number of hospital appointments required to achieve a specific diagnosis.</p><p> </p><p> </p><p> </p><p>Information about the average time from diagnosis to referral for specialist treatment is not available centrally. Patients suspected of having EDS may be assessed and diagnosed in a wide range of settings. These include United Kingdom regional clinical genetics clinics and various other secondary and tertiary speciality clinics.</p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 9988 9989 question first answered 21/09/2015 10:00:13 answering member 4020 label Biography information for George Freeman
	tabling member	4140 label Biography information for Mr David Nuttall

418454

	registered interest
	date	11/09/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Ehlers-Danlos Syndrome
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what recent discussions his Department has had with health bodies on ensuring timely treatment for sufferers of Ehlers-Danlos syndrome.
	tabling member constituency	Bury North
	tabling member printed	Mr David Nuttall
	uin	9988
	answer	answer is ministerial correction date of answer 21/09/2015 answer text <p>Information on patient outcomes of those diagnosed with Ehlers-Danlos Syndrome (EDS) in London and Greater Manchester is not held centrally by the Department. EDS falls within specialised services managed by NHS England.</p><p> </p><p> </p><p> </p><p>The UK Strategy for Rare Diseases sets out the Government’s on-going commitment to ensuring that patients with rare diseases, including EDS, have access to high quality services. The Strategy is discussed regularly with health bodies including NHS England. The national specialised service for atypical or complex cases aims to reduce times to diagnosis and reduce the number of hospital appointments required to achieve a specific diagnosis.</p><p> </p><p> </p><p> </p><p>Information about the average time from diagnosis to referral for specialist treatment is not available centrally. Patients suspected of having EDS may be assessed and diagnosed in a wide range of settings. These include United Kingdom regional clinical genetics clinics and various other secondary and tertiary speciality clinics.</p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 9987 9989 question first answered 21/09/2015 10:00:16 answering member 4020 label Biography information for George Freeman
	tabling member	4140 label Biography information for Mr David Nuttall

418457

	registered interest
	date	11/09/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Ehlers-Danlos Syndrome
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what the average length of time is between the diagnosis of a patient with Ehlers-Danlos syndrome and referral for specialist treatment in (a) London and (b) Greater Manchester.
	tabling member constituency	Bury North
	tabling member printed	Mr David Nuttall
	uin	9989
	answer	answer is ministerial correction date of answer 21/09/2015 answer text <p>Information on patient outcomes of those diagnosed with Ehlers-Danlos Syndrome (EDS) in London and Greater Manchester is not held centrally by the Department. EDS falls within specialised services managed by NHS England.</p><p> </p><p> </p><p> </p><p>The UK Strategy for Rare Diseases sets out the Government’s on-going commitment to ensuring that patients with rare diseases, including EDS, have access to high quality services. The Strategy is discussed regularly with health bodies including NHS England. The national specialised service for atypical or complex cases aims to reduce times to diagnosis and reduce the number of hospital appointments required to achieve a specific diagnosis.</p><p> </p><p> </p><p> </p><p>Information about the average time from diagnosis to referral for specialist treatment is not available centrally. Patients suspected of having EDS may be assessed and diagnosed in a wide range of settings. These include United Kingdom regional clinical genetics clinics and various other secondary and tertiary speciality clinics.</p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 9987 9988 question first answered 21/09/2015 10:00:17 answering member 4020 label Biography information for George Freeman
	tabling member	4140 label Biography information for Mr David Nuttall

418459

	registered interest
	date	11/09/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Ophthalmic Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what funding his Department provides for eye clinic liaison officers.
	tabling member constituency	Tewkesbury
	tabling member printed	Mr Laurence Robertson
	uin	9977
	answer	answer is ministerial correction date of answer 16/09/2015 answer text <p>The Government fully appreciates the impact that sight loss can have on a person’s life and the importance of information being available for those newly diagnosed with sight loss, including signposting patients to appropriate support and rehabilitation services.</p><p> </p><p> </p><p> </p><p>Eye clinics and their staffing, including eye clinic liaison officers, are commissioned and funded by individual clinical commissioning groups on the basis of local assessments of need.</p><p> </p> answering member constituency North East Bedfordshire answering member printed Alistair Burt grouped question UIN 9980 question first answered 16/09/2015 12:01:58 answering member 1201 label Biography information for Alistair Burt
	tabling member	253 label Biography information for Mr Laurence Robertson

418458

	registered interest
	date	11/09/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Ophthalmic Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what recent assessment he has made of the effect of eye clinic liaison officers on improving patient health and social care; and what progress he has made on increasing the provision of such officers.
	tabling member constituency	Tewkesbury
	tabling member printed	Mr Laurence Robertson
	uin	9980
	answer	answer is ministerial correction date of answer 16/09/2015 answer text <p>The Government fully appreciates the impact that sight loss can have on a person’s life and the importance of information being available for those newly diagnosed with sight loss, including signposting patients to appropriate support and rehabilitation services.</p><p> </p><p> </p><p> </p><p>Eye clinics and their staffing, including eye clinic liaison officers, are commissioned and funded by individual clinical commissioning groups on the basis of local assessments of need.</p><p> </p> answering member constituency North East Bedfordshire answering member printed Alistair Burt grouped question UIN 9977 question first answered 16/09/2015 12:01:58 answering member 1201 label Biography information for Alistair Burt
	tabling member	253 label Biography information for Mr Laurence Robertson

759375

	registered interest
	date	11/09/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Children: Food
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how his Department plans to work with the Scottish Government on protecting children from junk food marketing.
	tabling member constituency	Inverclyde
	tabling member printed	Ronnie Cowan
	uin	9910
	answer	answer is ministerial correction date of answer 18/09/2017 answer text <p>Departmental officials will continue to work with colleagues in the devolved administrations, sharing our thinking and progress to ensure children across the United Kingdom can have the best start in life.</p><p> </p><p>Current advertising restrictions in the UK on high fat, salt or sugar (HFSS) products are among the toughest in the world. Strict new rules came into effect on 1 July banning the advertising of HFSS food or drink products in children’s media. These restrictions apply across all non-broadcast media including in print, cinema, online and in social media.</p><p> </p><p>In August we announced £5 million investment in a policy research unit on childhood obesity to provide a robust evidence, evaluation and research capability including looking at the impact of marketing on childhood obesity. The unit’s findings will be fed into future meetings with colleagues across the UK.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 9911 9912 question first answered 18/09/2017 14:47:50 answering member 4067 label Biography information for Steve Brine
	tabling member	4465 label Biography information for Ronnie Cowan

759384

	registered interest
	date	11/09/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Children: Food
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps his Department plans to take to allow the Scottish Government to restrict junk food advertising to children.
	tabling member constituency	Inverclyde
	tabling member printed	Ronnie Cowan
	uin	9912
	answer	answer is ministerial correction date of answer 18/09/2017 answer text <p>Departmental officials will continue to work with colleagues in the devolved administrations, sharing our thinking and progress to ensure children across the United Kingdom can have the best start in life.</p><p> </p><p>Current advertising restrictions in the UK on high fat, salt or sugar (HFSS) products are among the toughest in the world. Strict new rules came into effect on 1 July banning the advertising of HFSS food or drink products in children’s media. These restrictions apply across all non-broadcast media including in print, cinema, online and in social media.</p><p> </p><p>In August we announced £5 million investment in a policy research unit on childhood obesity to provide a robust evidence, evaluation and research capability including looking at the impact of marketing on childhood obesity. The unit’s findings will be fed into future meetings with colleagues across the UK.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 9910 9911 question first answered 18/09/2017 14:47:50 answering member 4067 label Biography information for Steve Brine
	tabling member	4465 label Biography information for Ronnie Cowan

759383

	registered interest
	date	11/09/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Children: Food
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what discussions he has had with the Scottish Government on developing advertising powers to enable that government to protect children from junk food marketing.
	tabling member constituency	Inverclyde
	tabling member printed	Ronnie Cowan
	uin	9911
	answer	answer is ministerial correction date of answer 18/09/2017 answer text <p>Departmental officials will continue to work with colleagues in the devolved administrations, sharing our thinking and progress to ensure children across the United Kingdom can have the best start in life.</p><p> </p><p>Current advertising restrictions in the UK on high fat, salt or sugar (HFSS) products are among the toughest in the world. Strict new rules came into effect on 1 July banning the advertising of HFSS food or drink products in children’s media. These restrictions apply across all non-broadcast media including in print, cinema, online and in social media.</p><p> </p><p>In August we announced £5 million investment in a policy research unit on childhood obesity to provide a robust evidence, evaluation and research capability including looking at the impact of marketing on childhood obesity. The unit’s findings will be fed into future meetings with colleagues across the UK.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 9910 9912 question first answered 18/09/2017 14:47:50 answering member 4067 label Biography information for Steve Brine
	tabling member	4465 label Biography information for Ronnie Cowan

418256

	registered interest
	date	10/09/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Aspartame
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what research his Department has undertaken or commissioned on possible links between aspartame and (a) aggressive behaviour, (b) depression, (c) anxiety and (d) Graves' Disease.
	tabling member constituency	Bury North
	tabling member printed	Mr David Nuttall
	uin	9849
	answer	answer is ministerial correction date of answer 18/09/2015 answer text <p>We are advised by the Food Standards Agency (FSA) that all food additives, including sweeteners, are only permitted after a robust evaluation of their safety. The foods in which the sweeteners can be used and their conditions of use are regulated under harmonised European Union legislation on food additives.</p><p> </p><p> </p><p> </p><p>The results of an FSA funded study on aspartame were published in March 2015. The study was designed to examine whether self-diagnosed individuals exhibit any reactions which can be observed in a clinical setting, after consuming bars that do or do not contain aspartame. Participants showed no difference in their response whether they contained aspartame or not.</p><p> </p><p> </p><p> </p><p>As part of its systematic re-evaluation of all food additives, the European Food Safety Authority (EFSA) re-evaluated the safety of aspartame and concluded in December 2013 that 'aspartame and its breakdown products are safe for human consumption at current levels of exposure'. In undertaking their re-evaluation EFSA had access to all available, relevant scientific studies and data on aspartame.</p><p> </p><p> </p><p> </p><p>Officials in the FSA have regular discussions with industry, and other interested parties, on a range of issues. Since EFSA reaffirmed the safety on the current use of aspartame, these have not routinely included discussions on aspartame or other sweeteners.</p><p> </p><p> </p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 9850 9861 9862 question first answered 18/09/2015 09:47:50 answering member 3918 label Biography information for Jane Ellison
	tabling member	4140 label Biography information for Mr David Nuttall

418257

	registered interest
	date	10/09/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Artificial Sweeteners
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what research and discussions his Department has had with the food industry and relevant professional bodies over the safety of aspartame and other artificial sweeteners.
	tabling member constituency	Bury North
	tabling member printed	Mr David Nuttall
	uin	9850
	answer	answer is ministerial correction date of answer 18/09/2015 answer text <p>We are advised by the Food Standards Agency (FSA) that all food additives, including sweeteners, are only permitted after a robust evaluation of their safety. The foods in which the sweeteners can be used and their conditions of use are regulated under harmonised European Union legislation on food additives.</p><p> </p><p> </p><p> </p><p>The results of an FSA funded study on aspartame were published in March 2015. The study was designed to examine whether self-diagnosed individuals exhibit any reactions which can be observed in a clinical setting, after consuming bars that do or do not contain aspartame. Participants showed no difference in their response whether they contained aspartame or not.</p><p> </p><p> </p><p> </p><p>As part of its systematic re-evaluation of all food additives, the European Food Safety Authority (EFSA) re-evaluated the safety of aspartame and concluded in December 2013 that 'aspartame and its breakdown products are safe for human consumption at current levels of exposure'. In undertaking their re-evaluation EFSA had access to all available, relevant scientific studies and data on aspartame.</p><p> </p><p> </p><p> </p><p>Officials in the FSA have regular discussions with industry, and other interested parties, on a range of issues. Since EFSA reaffirmed the safety on the current use of aspartame, these have not routinely included discussions on aspartame or other sweeteners.</p><p> </p><p> </p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 9849 9861 9862 question first answered 18/09/2015 09:47:50 answering member 3918 label Biography information for Jane Ellison
	tabling member	4140 label Biography information for Mr David Nuttall